INmune Bio, Inc. (INMB)
NASDAQ: INMB · IEX Real-Time Price · USD
8.04
-0.04 (-0.50%)
Jul 22, 2024, 9:59 AM EDT - Market open
INmune Bio Employees
As of December 31, 2023, INmune Bio had 17 total employees, including 11 full-time and 6 part-time employees. The number of employees increased by 7 or 70.00% compared to the previous year.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
$7,706
Profits / Employee
-$2,029,235
Market Cap
174.48M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
TruBridge | 3,219 |
Rani Therapeutics Holdings | 140 |
Stereotaxis | 122 |
TriSalus Life Sciences | 112 |
Compugen | 68 |
Assertio Holdings | 53 |
Achieve Life Sciences | 22 |
FibroBiologics | 10 |
INMB News
- 7 weeks ago - INmune Bio Inc. to Join Russell 3000® Index - GlobeNewsWire
- 2 months ago - INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update - GlobeNewsWire
- 2 months ago - INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9 - GlobeNewsWire
- 2 months ago - INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years - GlobeNewsWire
- 3 months ago - INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 3 months ago - INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 3 months ago - INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay - GlobeNewsWire
- 3 months ago - INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering - GlobeNewsWire